title: 18F-FP-CIT PET imaging and SPM analysis of dopamine transporters in Parkinson's disease in various Hoehn & Yahr stages.
abstract: To investigate the usefulness of 18F-FP-CIT PET for assessing the severity of Parkinson's disease (PD) at various clinical stages, 41 patients with PD were divided into early (Hoehn&Yahr I-II, n = 23) and advanced (Hoehn & Yahr III-IV, n = 18) subgroups. 18F-FP-CIT PET was performed in these patients and 12 normal subjects. 18F-FP-CIT uptake in striatal subregions and its correlation with UPDRS were first evaluated by ROI analysis, and between-group differences were also analyzed by Statistical Parametric Mapping (SPM). Our results showed that striatal 18F-FP-CIT binding were significantly reduced to 70.9% (caudate), 46.8% (anterior putamen) and 24.0% (posterior putamen) in early PD compared with that of the control, and to 52.0%, 34.5% and 16.5% correspondingly in advanced PD, respectively. There was significant negative correlation between total motor UPDRS score of all parkinsonian patients and 18F-FP-CIT uptake in caudate nucleus (r = -0.53, p < 0.001), anterior putamen (r = -0.53, p < 0.001) and posterior putamen (r = -0.61, p < 0.001). SPM comparison of 18F-FP-CIT uptake between early or advanced PD and the control group showed significant decline in striatum, predominantly localized on the contralateral side and in the dorsal-posterior putamen. These results indicate that 18F-FP-CIT PET can serve as a suitable biomarker to represent the severity of PD in early and advanced stages.
authors.affiliation: Department of Neurology, Huashan Hospital affiliated to Fudan University, 12 Wulumuqi Zhong Road, Shanghai 200040, China. wangjian336@hotmail.com
authors.forename: Jian
authors.initials: J
authors.lastname: Wang
authors.forename: Cuan-Tao
authors.initials: CT
authors.lastname: Zuo
authors.forename: Yu-Ping
authors.initials: YP
authors.lastname: Jiang
authors.forename: Yi-Hui
authors.initials: YH
authors.lastname: Guan
authors.forename: Zheng-Ping
authors.initials: ZP
authors.lastname: Chen
authors.forename: Jing-De
authors.initials: JD
authors.lastname: Xiang
authors.forename: Li-Qin
authors.initials: LQ
authors.lastname: Yang
authors.forename: Zheng-Tong
authors.initials: ZT
authors.lastname: Ding
authors.forename: Jian-Jun
authors.initials: JJ
authors.lastname: Wu
authors.forename: Hui-Lin
authors.initials: HL
authors.lastname: Su
mesh_terms: D000368:Aged; D001931:Brain Mapping; D016022:Case-Control Studies; D050483:Dopamine Plasma Membrane Transport Proteins / Q000378:metabolism*; D005260:Female; D006801:Humans; D007091:Image Processing, Computer-Assisted; D008297:Male; D008875:Middle Aged; D010300:Parkinson Disease / Q000000981:diagnostic imaging* / Q000473:pathology / Q000503:physiopathology*; D049268:Positron-Emission Tomography; D011699:Putamen / Q000000981:diagnostic imaging; D012720:Severity of Illness Index; D014326:Tropanes / Q000378:metabolism; D014463:Ultrasonography
chemical_list: D050483:Dopamine Plasma Membrane Transport Proteins; D014326:Tropanes; C087552:2-carbomethoxy-8-(3-fluoropropyl)-3-(4-iodophenyl)tropane